Company profile
UK company 11504964, incorporated on 7 August 2018.
Producing elegant treatments for complex diseases | ikarovec
Ikarovec is a pre-clinical phase gene therapy company. Our programmes are aimed at treating common eye diseases, restoring sight and preventing blindness.
Company number 11504964
Updated 07 Jul 2026 09:49
Reference milestones and recent Companies House filing stream events.
Next confirmation statement due date
Next accounts due date
CS01 | Transaction MzU0Mjg0MTU0NGFkaXF6a2N4
Published 08 Sep 2026 07:09
AA01 | Transaction MzU0MTE3NzkyN2FkaXF6a2N4
Published 27 Aug 2026 07:08
Last confirmation statement made up date
Last accounts made up date
Company registered at Companies House
1 Dec 2025 to 30 Nov 2029
Diabetic Macular Oedema (DMO) is a severe complication of both type 1 and type 2 diabetes that significantly impairs vision and affects over 28 million people worldwide. Characterised by fluid build-up and leakage into the eye, DMO leads to central vision loss. In the UK, over 10% of diabetics suffer from DMO, costing the NHS over £100 million annually. A...
1 May 2024 to 31 Mar 2026
The development of gene therapies holds immense significance for medical innovation. Yet, the realization of their full therapeutic impact hinges on the urgent need for technological advancements that can further improve drug product (DP) quality and efficacy. Formulation, the penultimate operation prior to final fill, is crucial for robust stability that...
1 Jul 2020 to 31 Mar 2023
"Age-related macular degeneration (AMD) is an eye condition affecting the central part of the retina (the macula), which can make it difficult for patients to read, drive or recognise people's faces. The wet form of AMD (wAMD) can develop quickly, causing serious changes to central vision in a short period of time -- over days or weeks as the retina start...
